1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Issue 12 (30th October 2018) Authors: Castroviejo‐Bermejo, Marta; Cruz, Cristina; Llop‐Guevara, Alba; Gutiérrez‐Enríquez, Sara; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris‐Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Bonache, Sandra; Moles‐Fernández, Alejandro; Villacampa, Guil... Journal: EMBO molecular medicine Issue: Volume 10:Issue 12(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Issue 12 (30th October 2018) Authors: Castroviejo‐Bermejo, Marta; Cruz, Cristina; Llop‐Guevara, Alba; Gutiérrez‐Enríquez, Sara; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris‐Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Bonache, Sandra; Moles‐Fernández, Alejandro; Villacampa, Guil... Journal: EMBO molecular medicine Issue: Volume 10:Issue 12(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Issue 12 (30th October 2018) Authors: Castroviejo‐Bermejo, Marta; Cruz, Cristina; Llop‐Guevara, Alba; Gutiérrez‐Enríquez, Sara; Ducy, Mandy; Ibrahim, Yasir Hussein; Gris‐Oliver, Albert; Pellegrino, Benedetta; Bruna, Alejandra; Guzmán, Marta; Rodríguez, Olga; Grueso, Judit; Bonache, Sandra; Moles‐Fernández, Alejandro; Villacampa, Guil... Journal: EMBO molecular medicine Issue: Volume 10:Issue 12(2018) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. Issue 2 (9th May 2019) Authors: Pellegrino, Benedetta; Mateo, Joaquin; Serra, Violeta; Balmaña, Judith Journal: ESMO open Issue: Volume 4:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Current overview and special considerations for second breast cancer in Hodgkin lymphoma survivors. (January 2021) Authors: Bakkach, Joaira; Pellegrino, Benedetta; Elghazawy, Hagar; Novosad, Olga; Agrawal, Sanjit; Bennani Mechita, Mohcine Journal: Critical reviews in oncology/hematology Issue: Volume 157(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2). (February 2019) Authors: Montagna, Giacomo; Anderson, David; Bochenek-Cibor, Justyna; Bozovic-Spasojevic, Ivana; Campos, Conceicao; Cavallero, Sandro; Durutovic, Ivana; Gomez Cuadra, Manuel Oscar; Irfan, Tazia; Joly, Laetita; Kassem, Loay; Kolben, Theresa M.; Machacek, Martina; Mir Khan, Benazir; Nagvekar, Mayur; Pellegr... Journal: Breast Issue: Volume 43(2019) Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients' Need. Preliminary Results of the Victor-6 Study. (November 2017) Authors: Cazzaniga, Marina Elena; Cagossi, Katia; Valerio, Maria Rosaria; Russo, Salvatore; Casadei, Virginia; Scognamiglio, Giovanni; Cavanna, Luigi; Toniolo, Davide; Deconciliis, Erico Maria Romani; Melegari, Elisabetta; Stocchi, Lucia; Gebbia, Vittorio; Vandone, Anna Maria; Cursano, Maria Concetta; Pin... Journal: Breast Issue: Volume 36(2017) Page Start: S48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Prognostic risk factors for treatment decision in pT1a, b N0M0 HER2-positive breast cancers. (February 2016) Authors: Musolino, Antonino; Boggiani, Daniela; Sikokis, Angelica; Rimanti, Anita; Pellegrino, Benedetta; Vattiato, Rosa; Sgargi, Paolo; Falcini, Fabio; Caminiti, Caterina; Michiara, Maria; Leonardi, Francesco Journal: Cancer treatment reviews Issue: Volume 43(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. (May 2020) Authors: Musolino, Antonino; Boggiani, Daniela; Pellegrino, Benedetta; Zanoni, Daniele; Sikokis, Angelica; Missale, Gabriele; Silini, Enrico Maria; Maglietta, Giuseppe; Frassoldati, Antonio; Michiara, Maria Journal: Critical reviews in oncology/hematology Issue: Volume 149(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The future potential of genome-wide mutational profiles in HRD detection in breast cancer. (2nd January 2022) Authors: Pellegrino, Benedetta; Tommasi, Chiara; Solinas, Cinzia; Campanini, Nicoletta; Silini, Enrico Maria; Musolino, Antonino Journal: Expert review of molecular diagnostics Issue: Volume 22:Number 1(2022) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗